bilaterals.org logo
bilaterals.org logo

RCEP & intellectual property

An analysis of the leaked IP chapter proposed for the RCEP shows that Japan and South Korea are proposing intellectual property (IP) provisions referred to as TRIPS-plus, which go far beyond the obligations under the World Trade Organisation’s Agreement on Trade Related Aspects of Intellectual Property Rights (TRIPS).

The proposed provisions seek to extend pharmaceutical corporations’ patent terms beyond the usual 20 years and also would require data exclusivity that limits competition. Such provisions are a cause for great concern among public health groups over their potential adverse impact on access to affordable medicines.

RCEP also treats IP as an investment made by investor corporations, allowing private investment disputes (ISDS) to be raised against the host country whenever there is a threat to their IP. Treating IP as an investment, and subjecting it to treaty arbitration, can have undesirable impacts on the hard-bargained flexibilities in IP laws and on public health safeguards that countries like India have earned over the years.

Further, civil society groups have expressed concern about the copyright protection standards proposed under the RCEP IP Chapter which could stifle creativity and free speech.

The leaked IP chapter also pushes for accession by all RCEP member states to the 1991 Act of the International Convention for the Protection of New Varieties of Plants (UPOV 1991), to which only seven of the RCEP negotiating countries are already member. UPOV 1991 provides monopoly rights to plant breeder rights at the cost of farmers’ rights, making it illegal for farmers to save seeds of protected vartieties.

Data exclusivity provisions in the IP chapter may extend the patent protection periods of agrochemical products as well, putting upward pressure on food prices.

RCEP governments must recall their international, regional and national commitments to respect, protect and fulfill the right to health including the right to access affordable medicines. In their quest for greater economic integration, RCEP negotiating countries must not put the lives and health of millions of people in the Asia-Pacific region at risk.


Pressure intensifies on India over software and pharma patent protection in key Asian trade negotiations
Recently leaked documents show that India’s policies on software and pharmaceutical patents are firmly on the RCEP agenda.
Proposed trade pact clause on intellectual property could endanger India’s TB programme
A draft of the Regional Comprehensive Economic Partnership agreement reveals three clauses that could potentially hurt production of important generic drugs
RCEP - draft IP chapter (15 Oct 2015 version)
As published by KEI
RCEP - draft IP text from ASEAN (Oct 2014)
As published by KEI
RCEP - draft IP text from India (Oct 2014)
As published by KEI
RCEP - draft IP text from Japan (2014)
as leaked by KEI on 10 Feb 2015
RCEP - draft IP text from Korea (Oct 2014)
As leaked by KEI on 3 June 2015
RCEP and affordable medicines: Civil society reaches out to Minister of Commerce Suresh Prabhu
Civil society organisations, patient groups and health activists have been concerned about intellectual property provisions being discussed in RCEP which undermine access to medicines and affordable treatment for patients
RCEP and health: this kind of ‘progress’ is not what India and the world need
Concerns remain over the impact of RCEP negotiations on public health and access to medicines.
RCEP investment chapter presents a grave threat to access to medicines
Médecins Sans Frontières (MSF) raises concerns over provisions under negotiation in the RCEP investment chapter that threaten to restrict access to affordable medicines for millions of people
RCEP IP chapter: A serious threat to access to knowledge/cultural goods?
RCEP stands to adversely affect nearly half of the world’s population on areas like access to knowledge and access to medicines. We would like to highlight five issues related to access to knowledge/cultural goods, based on the leaked IP chapter.
RCEP negotiations should not restrict global access to affordable medicines and vaccines
RCEP negotiations should not restrict global access to affordable medicines and vaccines
RCEP talks could affect startups by allowing patenting of computer software
Several startups and civil society members fought hard over the last year to prevent the allowing of software patents in India.
RCEP talks in Indonesia focus on concessions, crafting of sensitive list
As the Trans-Pacific Partnership (TPP) made significant headway in January, negotiating countries in the Regional Comprehensive Economic Partnership (RCEP) are pressured to conclude the trade deal, and they try to make progress in the ongoing talks in Indonesia.
RCEP talks: Farmers, civil society bodies warn against obligations on patenting seeds, plant varieties
Farmer and CSOs stressing that India should not agree to obligations with respect to IP on seed and planting materials at the RCEP negotiations as it hurt the livelihood of poor farmers.
RCEP talks: India manages major breakthrough
New Delhi won’t not take additional commitment on intellectual property rights beyond the TRIPS agreement it has already accepted at the WTO; investor-state dispute settlement (ISDS) mechanism only for limited sectors.
RCEP: Corporations could sue governments
ISDS is increasingly being used by global corporations to challenge health, environment and other public interest laws.
RCEP: India in a Catch-22
India’s position in the RCEP is the most protectionist among all the member nations. India has been resisting demands from Korea & Japan on intellectual property clauses, and other nations on opening up markets.
RCEP: Robbing communities to extract profit
RCEP will give multinational corporations unprecedented rights
RCEP: The other closed-door agreement to compromise users’ rights
A secretive trade agreement currently being negotiated behind closed doors could lay down new, inflexible copyright standards across the Asia-Pacific region. If you are thinking of the Trans-Pacific Partnership, think again—we’re talking about the lesser-known Regional Comprehensive Economic Partnership (RCEP). While RCEP doesn’t include the United States, it does include the two biggest Asian giants that the TPP omits—China and India.